Advertisement: TTP Killer 50
27 March, 2019 - 13:55 By Kate Sweeney

Artios Pharma

Niall Martin of Artios Pharma

Artios Pharma, a leading DNA Damage Response company developing innovative treatments for cancer, completed an $84 million Series B financing in August 2018, with new global investors pitching into a significantly over-subscribed round. 

Artios, based at the Babraham Research Campus, is actively developing a pipeline of highly promising first-in-class DDR therapies identified from a global network of leading researchers in the field, including through Cancer Research UK. 

The inhibition of novel DNA repair targets like Polθ, in tumours where DNA damage response factors have been lost or down regulated, will lead to cancer cells being selectively killed without harming normal cells. This creates an opportunity for such products to be used both in monotherapy and in combination with existing and future cancer therapies. 

Job opportunities at Artios Pharma

Newsletter Subscription

Stay informed of the latest news and features